Diclofenac Uno Ratiopharm

Diclofenac Uno Ratiopharm is an oral medication that contains the active ingredient diclofenac sodium, a non‑steroidal anti‑inflammatory drug (NSAID) formulated for systemic use. It belongs to the analgesic, anti‑inflammatory and antirheumatic therapeutic class and is marketed in the European Union. The product is intended to provide pain relief and reduce inflammation in various musculoskeletal conditions. It is supplied as tablets for administration, and is prescribed when other options are insufficient.

Diclofenac Uno Ratiopharm is indicated for conditions where reduction of pain and inflammation is required.

- Relief of mild to moderate pain associated with osteoarthritis. - Management of rheumatoid arthritis symptoms. - Treatment of acute musculoskeletal injuries such as sprains, strains, and tendonitis. - Alleviation of postoperative pain following minor surgical procedures. - Control of chronic low‑back pain when other therapies are inadequate. - Reduction of inflammation in temporomandibular joint disorders. - Symptomatic relief of dysmenorrhea when NSAID therapy is appropriate. - It may be prescribed as part of a broader therapeutic plan that includes physical therapy or disease‑modifying agents.

The safety profile of Diclofenac Uno Ratiopharm reflects the typical effects observed with oral diclofenac sodium, ranging from frequent mild reactions to rare but serious adverse events. Patients should be monitored regularly, especially during long‑term therapy.

Common: - Gastrointestinal discomfort such as dyspepsia, nausea, or abdominal pain. - Headache or dizziness. - Mild elevation of liver enzymes. - Fluid retention leading to peripheral edema. - Skin rash or pruritus. - Increased blood pressure.

Serious: - Peptic ulcer disease or gastrointestinal bleeding. - Severe hepatic injury. - Renal impairment or acute kidney injury. - Cardiovascular events such as myocardial infarction or stroke. - Anaphylactic or severe hypersensitivity reactions. - Thromboembolic events such as deep vein thrombosis.

When prescribing Diclofenac Uno Ratiopharm, clinicians consider several precautionary factors to minimize risk and ensure appropriate use.

- Assess gastrointestinal risk, especially in patients with a history of ulcers or bleeding. - Evaluate cardiovascular status; avoid use in patients with uncontrolled hypertension or recent thrombotic events. - Review renal function before initiation and monitor during therapy, particularly in the elderly. - Use the lowest effective dose for the shortest duration necessary. - Consider alternative analgesics in patients with known hypersensitivity to NSAIDs. - Avoid use during the third trimester of pregnancy unless clearly indicated.

Diclofenac Uno Ratiopharm may interact with other medicines, altering its effectiveness or increasing the risk of adverse effects.

Avoid: - Concurrent use with other NSAIDs or COX‑2 selective inhibitors. - Combination with anticoagulants such as warfarin or direct oral anticoagulants. - Use with high‑dose aspirin therapy. - Avoid simultaneous use with corticosteroids, which can increase gastrointestinal ulcer risk.

Use with caution: - Concomitant administration with ACE inhibitors or diuretics may affect renal function. - Co‑administration with lithium can increase lithium serum levels. - Use together with methotrexate may raise methotrexate toxicity. - Combination with selective serotonin reuptake inhibitors (SSRIs) may elevate bleeding risk.